Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093002 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT00093002 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 179 participants.
The verdict
NCT00093002, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Interventions
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093002
The ClinicalTrials.gov registry entry for NCT00093002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fulvestrant is the first listed.
NCT00093002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093002 about?
NCT00093002 is a clinical study titled "Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer". The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
What is the current status of trial NCT00093002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2004-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00093002?
The interventions under investigation include: Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00093002?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.